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High-Throughput Chemical Screening for Antivirulence
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Centre for Immunity, Infection and Evolution, Institute for Immunology and Infection Research, School of Biological Sciences, University of Edinburgh, Edinburgh,a Centre
for Translational and Chemical Biology, School of Biological Sciences and School of Biomedical Sciences, University of Edinburgh, Edinburgh,b and Biological Chemistry
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In the bloodstream of mammalian hosts, the sleeping sickness parasite, Trypanosoma brucei, exists as a proliferative slender
form or a nonproliferative, transmissible, stumpy form. The transition between these developmental forms is controlled by a
density-dependent mechanism that is important for the parasite’s infection dynamics, immune evasion via ordered antigenic
variation, and disease transmissibility. However, stumpy formation has been lost in most laboratory-adapted trypanosome lines,
generating monomorphic parasites that proliferate uncontrolled as slender forms in vitro and in vivo. Nonetheless, these forms
are readily amenable to cell culture and high-throughput screening for trypanocidal lead compounds. Here, we have developed
and exploited a high-throughput screen for developmental phenotypes using a transgenic monomorphic cell line expressing a
reporter under the regulation of gene control signals from the stumpy-specific molecule PAD1. Using a whole-cell fluorescence-
based assay to screen over 6,000 small molecules from a kinase-focused compound library, small molecules able to activate
stumpy-specific gene expression and proliferation arrest were assayed in a rapid assay format. Independent follow-up validation
identified one hit able to induce modest, yet specific, changes in mRNA expression indicative of a partial differentiation to
stumpy forms in monomorphs. Further, in pleomorphs this compound induced a stumpy-like phenotype, entailing growth ar-
rest, morphological changes, PAD1 expression, and enhanced differentiation to procyclic forms. This not only provides a poten-
tial tool compound for the further understanding of stumpy formation but also demonstrates the use of high-throughput
screening in the identification of compounds able to induce specific phenotypes, such as differentiation, in African
trypanosomes.
Members of the order Kinetoplastida comprise a highly diver-gent group of eukaryotic organisms, with several represen-
tatives causing life-threatening and debilitating human diseases in
a human-human or zoonotic transmission cycle. Trypanosoma
brucei sp. is a blood-dwelling parasitic organism of this order,
transmitted by tsetse flies, that causes both human and animal
African trypanosomiasis (HAT and AAT, respectively) in sub-Sa-
haranAfrica. These diseases causemorbidity and then deathwhen
untreated in humans (1) and significantly contribute to poverty
and restrict economic development in afflicted regions. Due to the
poor safety and efficacy of current drugs, new treatments for Af-
rican trypanosomiasis are urgently required (2, 3), and, conse-
quently, considerable efforts are being made to search for new
trypanocidal compounds.One approach has been throughwhole-
cell-based high-throughput screening (4–10) where thousands of
small molecules are rapidly analyzed for antiparasitic activity,
identifying classes of lead compounds with potential for further
development as antitrypanosomal drugs (6, 7, 9, 10). In addition
to the use of high-throughput chemical inhibitor screens for the
identification of compounds with antiparasitic properties, similar
approaches have been used in Plasmodium falciparum and Toxo-
plasma gondii to search for small molecules able to induce specific
cytological phenotypes (11–13), providing potential novel thera-
peutic approaches and tool compounds for biological research
(14).
In the bloodstream of their mammalian host, African trypano-
somes differentiate from the proliferative slender form to the
transmissible stumpy form (15), a transition that is key to the
within-host infection dynamics and transmissibility of the para-
site (16). In naturally occurring pleomorphic cell lines, stumpy
formation is triggered by parasite density, as sensed through the
accumulation of an unidentified stumpy induction factor (SIF)
(17). Although laboratory-adapted monomorphic bloodstream
forms have lost the ability to differentiate to stumpy forms in
response to population density in vitro or in vivo, these cell lines do
have the capacity for differentiation to a “stumpy-like” state when
treated with cell-permeable cyclic AMP (8-pCPT-cAMP) and,
more potently, the hydrolysis products of these compounds and
cell-permeable AMP, 8-pCPT-2=-O-methyl 5=-AMP (16–19). In
response to these stimuli, monomorphic cells undergo cell cycle
arrest, demonstrate an increased capacity for differentiation to the
procyclic stage, and undergo changes in gene expression associ-
ated with stumpy formation (16–18). It has been hypothesized
that cAMP analogues act to mimic the induction of stumpy for-
mation, bypassing the initial step(s) of environmental density
sensing and triggering at least part of the stumpy induction signal-
ing cascade within the cell. Until recently, very little was known
regarding the molecules involved in stumpy formation, with only
negative regulators TbTOR4 kinase (Tb927.1.1930), which pre-
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vents stumpy formation inmonomorphic slender forms (20), and
two further inhibitory kinases, mitogen-activated protein kinase 5
(MAPK5) (Tb927.6.4220) (21) and zinc finger kinase (ZFK)
(Tb927.11.9270) (22), having been identified. However, recently,
promoters of stumpy formation have also been identified based
on the selection of monomorphic RNA interference (RNAi) li-
braries for resistance to cell-permeable cAMP/AMP analogues,
and these promoters have been further validated in vivo using
pleomorphs for SIF responsiveness. Hence, a cohort of molecules
representing many steps in the signal response leading to stumpy
formation have now been identified, with small-molecule drivers
of the stumpy-like response having been central to identification
of the pathway components. Clearly, this knowledge of the
stumpy induction pathway could also lead to novel therapeutic
approaches sincemolecular inhibitors of stumpy formation could
be targeted to induce premature development in the bloodstream,
reducing parasite virulence or reducing abundance below a trans-
mission threshold. Alternatively, molecular drivers of stumpy for-
mation could be activated to achieve the same therapeutic out-
come. Hence, compounds promoting developmental arrest in the
parasite have value as biological tool compounds as well as offer-
ing novel approaches to disease control (20–22).
Wehave previously demonstrated that transgenic cell lines that
utilize reporter genes (12) coupled to the 3= untranslated region
(UTR) of the PAD1 gene (Tb927.7.5930), a functional molecular
marker for stumpy forms (23), can report on the response of
monomorphic slender cells to conditions that promote the pro-
duction of stumpy-like forms (16). Here, we have built on this
system to develop a simple high-throughput assay for the detec-
tion of stumpy-like induction in monomorphic cell lines. This
assay has been used to screen over 6,000 kinase-focused inhibitors
for their ability to induce PAD1 3= UTR-regulated reporter ex-
pression as a proxy for the induction of stumpy formation. This
led to the identification of two structurally similar compounds
that caused an unspecific increase in reporter expression as well as
one chemically distinct compound that not only caused an up-
regulation of PAD1 mRNA expression but also generated consis-
tent changes in mRNA expression for a small set of genes that are
representative of partial stumpy formation in monomorphs and
that also generate a stumpy-like phenotype in pleomorphic cell
lines. This demonstrates the validity of a reporter screen for
stumpy formation and of the use of high-throughput screening
for the identification of small compounds that induce not only the
cytocidal or cytostatic outcomes routinely analyzed but also spe-
cific phenotypic responses useful for the molecular analysis of
trypanosome biology.
MATERIALS AND METHODS
Trypanosoma brucei cell lines and culturing. Lister 427 cells were trans-
fected with the pHD617 glucuronidase (GUS)-PAD1 3= UTR reporter
construct modified from pHD617 chloramphenicol acetyltransferase
(CAT)-PAD1 3= UTR (16, 24) to generate the cell line 427 GUS-PAD1 3=
UTR used for compound screening. The previously described (16) 427
CAT-PAD1 3= UTR GUS-Const 3= UTR cell line was utilized for fol-
low-up analysis (16). Trypanosomes were grown in HMI-9 medium with
20% fetal calf serum (FCS) at 37°C in 5% CO2 (25).
Differentiation experiments and assays of stumpy formation. Dif-
ferentiation of bloodstream forms to procyclic forms was induced by ad-
dition of 6 mM cis-aconitate and a temperature reduction from 37°C to
27°C. Differentiation capacity was determined by EP procyclin expres-
sion, measured by flow cytometry. Cell cycle analysis was carried out by
4=,6=-diamidino-2-phenylindole (DAPI) staining of fixed cells (100 ng/
ml) and analysis via flow cytometry (26). For phase-contrast/DAPI mi-
croscopy, cells were fixed in ice-cold methanol and stained with 1 g/ml
DAPI. PAD1 protein expression was measured either by immunofluores-
cence microscopy with cells fixed for 10 min in 3% ice-cold paraformal-
dehyde (PFA) and stained using an anti-PAD1 antibody (23), by staining
fixed cells for PAD1 protein and analyzing via flow cytometry, or byWest-
ern blot, carried out as previously described (23), with protein detected
using Pierce ECL Western blotting substrate. 8-pCPT-cAMP was pur-
chased from Sigma-Aldrich (United Kingdom).
Compound screening. The compound screening was carried out at
the Drug Discovery Unit at the University of Dundee using a kinase-
focused compound library from the Scottish Hit Discovery Facility. A
kinase inhibitor library was chosen for two reasons: first, kinases play an
important role in many cell processes, including stumpy formation (20–
22), and, second, kinases have been proposed as good drug targets in
trypanosomes (27–29). The 427 GUS-PAD1 3= UTR cell line was plated
into 96-well plates at 5 105 cells/ml at 100l/well. Cells were treated for
48 h with test compounds at 50 M in single cultures during primary
screening and at 5.6M,16.7M, and 50Minduplicate cultures during
secondary screening in 0.5% (vol/vol) dimethyl sulfoxide (DMSO). This
initial 50 M concentration was chosen for primary screening based on
standard screening procedures at the Drug Discovery Unit and because
the positive control for induction of a stumpy-like form in vitro is rou-
tinely used at 100 M 8-pCPT-cAMP (16) (Sigma, United Kingdom).
Secondary screening was carried out in a titration series to assess hit po-
tency although for tool compound development this is less important
than phenotypic specificity. Screen performance was determined via in-
ternal controls (see Fig. 2), with a Z= score (based on GUS enzyme assay)
of 0.61  0.13 for primary screening and 0.58  0.12 for secondary
screening (mean standard deviation). The purity andmolecularmass of
all hit compounds were determined by liquid chromatography-mass
spectrometry.
GUS enzyme activity was measured via the addition of an equal vol-
ume of 4-methylumbelliferyl--glucopyranosiduronic acid (MUG;
Sigma, United Kingdom) in lysis buffer (1 mM MUG, 0.82 M Tris-HCl,
pH 8, 0.6% SDS, 0.3mg/ml bovine serum albumin [BSA]) andmeasuring
fluorescence at an excitation wavelength (ex) of 340 nm and emission
wavelength (em) of 460 nm after a 2-h incubation. Hit identification was
based on results from a GUS enzyme assay only; however, for a mea-
sure of cell growth, 10% (vol/vol) alamarBlue was also added to the
cells, and fluorescence was measured at ex of 530 nm and em of 590
nm after a 4-h incubation (30). The alamarBlue assay was carried out
immediately prior to the GUS assay, and no cross talk was observed.
Fluorescence measured in GUS assays carried out during follow-up
analysis was corrected for cell number. Addition of pCPT-cAMP, com-
pound DDD00070762, or compound DDD00015314 to HMI-9 me-
dium did not cause any increase in background fluorescence compared
to DMSO-treated HMI-9 medium.
Validation analysis using a CAT-based reporter was also used. Here,
CAT protein levels were determined by CAT enzyme-linked immunosor-
bent assay (ELISA; Roche) according to the manufacturer’s instructions,
with absorbance being measured using a BioTek ELx808 Absorbance Mi-
croplate Reader. Statistical analysis was carried out usingMinitab, version
16, with data analyzed using general linear models (GLMs). Transforma-
tion of datawas carried out to satisfy assumptions of normality.P values of
less than 0.05 were considered significant.
RNA sequencing. RNA samples for analysis by high-throughput
sequencing of RNA transcripts (RNA-Seq) were harvested from CAT-
PAD1 3= UTR GUS-Const 3= UTR cells after treatment with 50 M
DDD00015314 or 0.5% (vol/vol) DMSO, in duplicate, for 24 h. Library
construction and sequencing were carried out by BGI-Hong Kong
using an Illumina TruSeq RNA Sample Preparation Kit. The quality of
raw sequence data was assessed using FastQC (http://www.bioinformatics
.babraham.ac.uk/projects/fastqc/). Paired-end sequences were aligned to the
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Trypanosoma brucei brucei genome (obtained from ftp.sanger.ac.uk/pub4
/pathogens/Trypanosoma/brucei/Latest_Whole_Genome_Sequence/Tb927
_WGS_24_08_2012/chromosomes/) using Bowtie2 (parameters, very-sen-
sitive-local; version 2.0.2); the outputs were filtered to remove alignments
flagged with the XS Sequence Alignment/Map (SAM) flag, yielding an
alignment data set that included only reads thatmap to a single location in
the reference genome. These data were subsequently sorted and indexed
using samtools. The annotated Trypanosoma brucei brucei genome was
viewed using Artemis software (http://www.sanger.ac.uk/resources
/software/artemis/ and http://ukpmc.ac.uk/abstract/MED/11120685),
and coding segment (CDS) region coordinates were extracted prior to
conversion to bedtools bedfile format. Bedtools (version 2.15.0; parame-
ters, multicov, -bams) was used to generate coverages for each CDS for
each sample replicate. Reads per kilobase per million reads mapped
(RPKM) values were calculated by dividing coverage by CDS size using
only reads that mapped to a single location in the reference genome
(RPKM-like). Statistical analyses of the two sample groups were under-
taken in the R environment (www.R-project.org) using Bioconductor
(www.bioconductor.org) packages. Differential expression was explored
using linear models and empirical Bayes methods, using the limma pack-
age (31). RPKM-like values were offset by 1, logged, and quantile normal-
ized prior to group-wise comparison. Postcomparison, data were filtered
to remove loci whose normalizedmean RPKM-like values were below the
20% quantile for all samples.
Meta-analysis of the log2 expression data fromCapewell et al. (32) and
Jensen et al. (33) required identification of overlapping gene sets, achiev-
able using systematic gene names. However, as there have been many
improvements in both the sequence and annotation of the Trypanosoma
brucei brucei 927 genome, some loci had been renamed, with the previous
names retained in their annotation.Using simple parsing scripts, a table of
current and previous gene names was generated, thereby facilitating data
set comparisons.
Nucleotide sequence accession number. RNA sequence data have
been deposited in the NCBI Gene Expression Omnibus (GEO) repository
under accession number GSE46483.
RESULTS
Validation of the reporter system.The 3=UTR of the PAD1 gene
has been shown, at least in part, to control its stumpy-specific
gene expression (16). By coupling the PAD1 3= UTR to a re-
porter gene, it is possible to monitor the increase in expression of
reporter activity as an indicator of stumpy-like formation or the
induction of stumpy-enriched mRNA expression. This method
has been used previously for the analysis of known chemical in-
ducers of stumpy-like formation via a CAT reporter gene (16),
where treatment with cell-permeable cAMP (8-pCPT-cAMP) or a
cAMP analogue (8-pCPT-2=-O-methyl-cAMP) caused an in-
crease in CATmRNA and protein expression as well as cell growth
arrest andmore efficient in vitro differentiation to procyclic forms
after exposure to 6mM cis-aconitate.Hence, these analogues drive
the expression of several characteristics associatedwith physiolog-
ical stumpy formation, there being an intersection between the
molecules responsible for response to these analogues and the
response to SIF itself (26). Nonetheless, it should be noted that
while cell-permeable cAMP is able to induce upregulation of pro-
tein levels of reporter genes coupled to the PAD13=UTR inmono-
morphic cell lines, it does not induce upregulation of the PAD1
protein itself (see Fig. S1 in the supplementalmaterial), suggesting
that there are additional levels of expression control operating on
PAD1 in these cells.
High-throughput screening for reporter activation. For
the purposes of high-throughput screening, it was necessary to use
a reporter that could be monitored quickly and cost effectively on
a large scale. Hence, a -glucuronidase reporter able to convert a
nonfluorescent substrate into a fluorescent product was selected
such that reporter activity could be measured in a rapid, simple,
and economical assay. For the assay, a substrate/lysis buffer was
added to whole cells, and fluorescence was measured, providing
compatibility with a 96-well plate format. An expression vector
was created that coupled the GUS reporter gene to the PAD1 3=
UTR (Fig. 1A), and this was transfected into T. brucei s427mono-
morphic cells to create the 427 GUS-PAD1 3=UTR cell line. Upon
induction with 8-pCPT-2=-O-Me-cAMP (16, 18), these cells up-
regulated GUS reporter activity, confirming their ability to re-
spond appropriately in the phenotypic screen (Fig. 1B). This also
confirmed the ability of the PAD1 3= UTR to respond to a stumpy
trigger regardless of the reporter gene used.
The 427 GUS-PAD1 3= UTR cell line was used to carry out a
pilot screen of small molecules with the aim of identifying novel
chemical inducers of stumpy formation. The screen was carried
out at the Drug Discovery Unit at the University of Dundee using
a kinase inhibitor-focused small-molecule library composed of
6,764 molecules (Fig. 2), according to the work flow outlined in
Fig. 3A. First, in a primary screen, 100 l of 5  105 cells/well of
the 427 GUS-PAD1 3= UTR cell line was incubated with a 50 M
concentration of each of the compounds from the library for 48 h
in 96-well plates (Fig. 2). Prior to monitoring for GUS reporter
activity, an alamarBlue assay (30) was carried out in order to pro-
vide a simplemeasure of cell proliferation; as stumpy formation is
associated with cell cycle arrest (15), it was expected that any com-
pound causing differentiation would also cause a decrease in pro-
liferation of the population (data not shown). On all plates, wells
treated with 100 M 8-pCPT-cAMP were included as a positive
control and as a benchmark for reporter activation (16, 17), with
activation of the reporter and inhibition of cell proliferation in-
duced by the 8-pCPT-cAMP set at 100% change. Given that this
reports on a developmental transition (as opposed to enzymatic
activity alone), physiologically relevant hit compounds would not
be expected to generate a response significantly greater than that
of the positive control (Fig. 2A). As such, compounds able to
generate53%GUS reporter activity, as determined through pri-
mary screening (Fig. 2B), were selected for secondary screening
(mean Z=, 0.61) (Fig. 2A). This cutoff was selected to include the
top200 hits, a number suitable for secondary screening.
The selected compounds were next subjected to secondary
screening whereby each compound was tested in duplicate at 5.6
M, 16.7 M, and 50 M (see Data Set S1 in the supplemental
material). From secondary screening, 162 compounds generated
fluorescence with a mean of 53% at 50 M, providing a signal
confirmation rate of the assay of 81.8% (mean Z=, 0.58). All 162
compounds were examined viamass spectrometry to confirm pu-
rity and identity. Compounds that failed this analysis were re-
moved, leaving 115 compounds. Since many of these generated
signals far greater than 8-pCPT-cAMP, it was anticipated that bi-
ologically irrelevant hits would comprise a significant proportion
of these. Therefore, these 115 compounds were tested for auto-
fluorescence in the absence of trypanosomes. This step deter-
mined that 112 of the 115 compounds exhibited autofluorescence
under the conditions used in the screen (ex of 340 nm and em of
460 nm) and, hence, likely represented false-positive results (see
Data Set S1). To confirm that this group did not contain a signif-
icant proportion of biologically active autofluorescent com-
pounds, a small selection of these 112 compounds were analyzed
MacGregor et al.
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for their ability to induce stumpy reporter activation using an
independent, nonfluorescent CAT reporter-based assay, with
each exhibiting no activity although some of the compounds did
affect cell growth (data not shown; see Fig. S2 in the supplemental
material). Thus, to stringently select for compounds that repre-
sent biologically relevant hits with respect to the phenotypic
screen used, all 112 autofluorescent compounds were excluded
from further analysis, identifying three hits from a primary screen
of 6,764molecules (Fig. 3B). This apparently low hit rate of 0.04%
highlights the selectivity of the screen for a differentiation-specific
response; a far higher number of compounds (37% in the primary
screen) caused trypanocidal or trypanostatic growth effects (as
measured by alamarBlue assay), probably through multiple spe-
cific and nonspecific cellular mechanisms.
Reporter and phenotypic confirmation of screen outputs.
Relative to 100 M 8-pCPT-cAMP, the three hit compounds
identified were able to activate the GUS reporter gene at levels
between 58% and 77% at 50 M (Fig. 3C). Each compound also
caused a decrease in alamarBlue activation, indicative of a reduc-
tion in population growth of between 31% and 123%, where
100% inhibition is that caused by 100 M 8-pCPT-cAMP
(Fig. 3D). Of the three compounds, DDD00070762 and
DDD00070827 were structurally related (Fig. 3B), and the third
was chemically distinct.
Of the two related compounds identified, compound
DDD00070762 was chosen for validation and follow-up analysis.
This compound demonstrated a 77% activation level of the GUS
reporter activity during screening (Fig. 3C) and also caused re-
duced population growth as measured by an alamarBlue assay
(Fig. 3D). For validation, 427 CAT-PAD1 3= UTR GUS-Const 3=
UTR cells were used that have the CAT reporter gene under PAD1
3= UTR control linked to a constitutively expressed GUS reporter
(this provides a measure of constitutive gene expression in the
presence of the compound in addition to stumpy-specific expres-
sion changes within the same cell line) (16). Treatment of these
cells with 50 M compound DDD00070762 stopped population
growth within 24 h (Fig. 4A) and caused upregulation of CAT
reporter gene expression after 24 and 48 h (Fig. 4B). This result
confirmed that DDD00070762 promoted stumpy-specific re-
porter gene expression in an independent, non-fluorescence-
based assay, validating the results of the high-throughput screen.
It was also observed, however, that the control GUS reporter gene
FIG 1 Regulation of GUS reporter gene expression by the PAD1 3= UTR. (A) Schematic representation of the pHD617 GUS-PAD1 3= UTR reporter construct
used to create the 427 GUS-PAD1 3= UTR cell line used for compound screening. This vector was modified from those described in MacGregor et al. and
Biebinger et al. (16, 24). Also shown are the pHD617 CAT-PAD1 3=UTR and pHD617 GUS-Const 3=UTR reporter constructs previously used to create the 427
CAT-PAD1 3= UTR GUS-Const 3= UTR cells (16), which are utilized in this study for follow-up analysis. The vector integrates into the ribosomal spacer locus
via a ribosomal integration site sequence (RITS). (B)Monomorphic bloodstream formT. brucei cells transfected with the pHD617GUS-PAD1 3=UTR construct
(427 GUS-PAD1 3= UTR cells) showed an increase in GUS reporter activity when treated with 10 M 8-pCPT-2=-O-Me-cAMP. Treatment with 0.5% (vol/vol)
DMSO had no effect on reporter activity. Error bars represent standard errors of the means (n	 3).Puro, puromycin; Hygro, hygromycin.
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expression was highly variable between analyses (data not shown)
and that within 24 h of treatment,80% of the cells had become
multinucleated (Fig. 4C). This contrasted with the small number
of cells (
5%) that showed aberrant cell cycle types after 24 h of
8-pCPT-cAMP treatment, where multinucleated cells were not
frequently observed. Indeed, while 8-pCPT-cAMP treatment
causes monomorphic cells to display a somewhat atypical mor-
phology after 48 h (Fig. 4D), this was distinct from the misshapen
multinucleated cells that arose after only 24 h of DDD00070762
treatment. Hence, although the stumpy-linked reporter gene was
upregulated by DDD00070762, this was not associated with
other hallmarks of a physiological differentiation to stumpy-
like forms. Rather, the compound appeared to cause consider-
able cell cycle and morphological defects unrelated to stumpy
formation, and therefore DDD00070762 and the structurally
related DDD00070827 were excluded from further analysis.
DDD00015314 drives stumpy-enriched gene expression.
Compound DDD00015314, N-(3-bromophenyl)-3-[(3-oxo-4H-
1,4-benzoxazin-6-yl)sulfonyl] propanamide, did not show any
structural similarities to either of the other two hits from the
screen (Fig. 3B). This compound demonstrated a 68% activation
of the GUS reporter activity during screening (Fig. 3C) and also
caused a modest reduction in population growth, as measured by
the alamarBlue assay (Fig. 3D). For validation, 427 CAT-PAD1 3=
UTRGUS-Const 3= UTR cells were treated with a 50M concen-
tration of the compound. As in the primary screen, this caused a
modest reduction in population growth (Fig. 5A) to 43.6% of that
of negative controls over 48 h. Also, a 2.5-fold increase in stumpy-
specific reporter gene expression was reproducibly observed after
24 h of treatment (Fig. 5B) (DMSO-treated cells versus
DDD00015314-treated cells at 24 h, F1,4 	 104.51, P 	 0.001),
which was not accompanied by any corresponding increase in the
constitutive GUS reporter (Fig. 5C) (DMSO-treated cells versus
DDD00015314-treated cells at 24 h, F1,4	 4.92, P	 0.091). This
is distinct from 8-pCPT-cAMP treatment, which results in re-
duced levels of GUS reporter expression, likely reflecting cellular
quiescence of the treated parasites (34). This result demonstrated
that DDD00015314 generated specific activation of the stumpy
reporter although no morphological changes in the treated cells
were observed by microscopy (data not shown). Hence, the over-
all response appeared to be less robust than with 8-pCPT-cAMP,
but the compound nonetheless generated specific and reproduc-
ible activation of the reporter expression in monomorphic cells.
The specific increase in stumpy reporter gene expression in-
FIG 2 Scattergram of the results of primary screen. During primary screening, the 427 GUS-PAD1 3= UTR cell line was treated with a 50 M concentration of
6,764 compounds for 48 h. (A) In 96-well plates, eight wells on each plate contained 100 M 8-pCPT-cAMP (positive control), and eight wells contained 0.5%
(vol/vol) DMSO (negative control). The percent activation of the GUS reporter activity across all control wells during primary screening is shown, with themean
of all wells for 8-pCPT-cAMP treatment set at 100%. (B) Results of primary screening with 198 compounds; those showing53% activation of GUS reporter
activity were classified as possible hits.
MacGregor et al.
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duced by DDD00015314 suggested that the compound promoted
some aspects of development to stumpy forms or stumpy-en-
riched gene expression. To investigate this, transcriptome analysis
via RNA-Seq was carried out on treated and control cells to mon-
itor global changes in gene expression in response to compound
exposure. RNA samples were harvested from cells after treatment,
in duplicate, for 24 hwith 50MDDD00015314 or 0.5% (vol/vol)
DMSO. The resulting total RNA was then subjected to RNA-Seq
analysis following Illumina TruSeq RNA Sample Preparation
(BGI, Hong Kong). Over 13 million 90-bp reads were generated
per sample, with a quality score of 20 (Q20; i.e., error rate of1%)
in95.5% of all samples. Raw sequence data were aligned to the
Trypanosoma brucei brucei 927 genome, and reads per kilobase per
million mapped reads (RPKM) were calculated for each CDS for
each sample replicate, including only reads that map to a single
location in the reference genome.
Pairwise comparison between the populations treated with
DDD00015314 or 0.5% (vol/vol) DMSO revealed a correlation
of 0.995 (Fig. 6A), suggesting that treatment with 50 M
DDD00015314 caused little general perturbation of gene expres-
sion, despite the slowed growth of the treated cells, and revealing
considerable consistency in the respective sample replicates. Nev-
ertheless, 95 genes were identified as upregulated, and 71 genes
were downregulated, with a 1.25-fold change after DDD00015314
treatment (see Data Set S2 in the supplemental material) and a
P of 
0.05 before adjustment for multiple testing, with no
genes showing a significant change after adjustment for multi-
ple testing. Table 1 shows a truncated list of genes up- and
downregulated after DDD00015314 treatment, with all hypo-
thetical (47/95 upregulated, 27/71 downregulated), variant
surface glycoprotein (VSG; 3/95 upregulated, 6/71 downregu-
lated), and retrotransposon hot spot protein (5/95 upregu-
lated) genes removed for clarity.
As expected, complete differentiation from slender to stumpy
forms did not occur upon DDD00015314 treatment; differentia-
tion to stumpy forms is associatedwith large-scale changes in gene
expression (32, 33, 35, 36), whereas DDD00015314 treatment
caused changes inmRNA expression only for a limited number of
genes. Nonetheless, of the changes that did occur, many were as-
sociated with transcript changes known to occur during stumpy
formation, and clear expression trends were observed with func-
tionally coordinated transcripts being coregulated (Table 1 and
Fig. 6B). Further, while these changes appearmodest (i.e.,
2-fold
change between treated and untreated cells), the changes observed
during complete physiological differentiation from slender to
stumpy forms are also in this range (Table 1, columns 5 and 6; see
also Table S1 in the supplemental material) (32, 33). As the cell
line used for this transcript analysis expressed the CAT reporter
gene coupled to the PAD1 3=UTR, it was also possible to monitor
themRNAexpression levels of theCAT reporter gene aswell as the
endogenous PAD1 gene itself. This revealed good agreement be-
tween the two transcripts, with a 1.47-fold upregulation of CAT
mRNA in response to DDD00015314 treatment and a 1.44-fold
increase in PAD1 mRNA expression (Table 1). A corresponding
upregulation of the PAD1 protein was not expected since the ex-
pression of this protein appears to be restricted in monomorphic
FIG 3 Three hit compoundswere identified through screening for the ability to induce stumpy-specific reporter gene expression. (A)Overview ofworkflowused
to identify three hit compounds from a library of 6,764 small molecules. (B) Structures of three hit compounds. (C) Percent GUS reporter activity after 48 h of
treatment as measured during secondary screening for each of the three hit compounds at 5.6 M, 16.7 M, and 50 M, where 100% activation is that caused
by 100M8-pCPT-cAMP. (D) Percent inhibition of alamarBlue activity after 48 h of treatment asmeasured during secondary screening for each of the three hit
compounds at 5.6M, 16.7M, and 50M, where 100% inhibition is that caused by 100M8-pCPT-cAMP. Data points represent themean of two replicates,
with error bars representing the range.
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cells (see Fig. S1 in the supplemental material). Supporting spec-
ificity of the observed changes, the mRNA expression level of the
constitutively expressed GUS reporter in the same cell lines was
unchanged compared to that in untreated cells (1.06-fold differ-
ence).
Analyzing the regulated changes after exposure of cells to
DDD00015314 demonstrated the elevation of several stumpy-en-
riched transcripts. These included PAD2, known to be upregu-
lated in stumpy and procyclic forms (23) (upregulated 1.37-fold),
and two ESAG9 genes (Tb927.7.170 and Tb927.9.7340), also
known to be enriched in stumpy forms (37). Similarly, themRNA
levels of two procyclic form surface proteins (Tb927.6.150 and
Tb927.10.11220) were also increased, consistent with their eleva-
tion in stumpy forms in preparation for expression upon differ-
entiation to procyclic forms in the tsetse midgut. Indeed, GPEET
is the predominant surface protein found on early procyclic forms
(38), andmultiple genome-wide analyses have shown that mRNA
expression of Tb927.6.150, aGPEET2precursor, is upregulated in
stumpy forms compared to levels in slender forms (33, 35, 36).
Similarly, Tb927.10.11220, or PSSA-2, is a procyclic-form phos-
phoprotein that has been shown by Northern blotting to have
greatly increased mRNA expression in procyclic forms compared
to bloodstream slender forms (39), which is preceded by its up-
regulation also in stumpy forms compared to slender forms (33,
35, 36).
Most notably, a number of genes associated with metabolism
were seen to have altered mRNA expression after DDD00015314
treatment (Fig. 6B). Slender bloodstream form trypanosomes
have a repressed mitochondrion and generate ATP solely from
glucose through glycolysis, with most of this pathway localized
within the glycosomes (40–42). Stumpy forms, however, have a
partially elaborated mitochondrion in preparation for differenti-
ation to the procyclic form (43), which has a fully developed mi-
tochondrion and can metabolize amino acids, particularly pro-
line, as well as glucose. Notably, DDD00015314 treatment caused
upregulation of 10 mitochondrial proteins and five proteins in-
volved in amino acid metabolism or transport, including proline
dehydrogenase and glutamate dehydrogenase (Tb927.7.120 and
Tb927.9.5900, 1.30-fold and 1.32-fold upregulated, respectively).
Conversely, there was a downregulation of 10 glucose trans-
porter gene transcripts and 13 glycosomal proteins, including
proteins that play a role in glycolysis (Table 1 and Fig. 6B). Thus,
FIG 4 Compound DDD00070762 causes upregulation of stumpy reporter gene expression but not stumpy formation. 427 CAT-PAD1 3= UTR GUS-
Const 3= UTR cells were treated with 50 M DDD00070762. Negative-control cells were treated with 0.5% (vol/vol) DMSO; positive-control cells were
treated with 100 M 8-pCPT-cAMP. (A) Population growth was monitored at 24 and 48 h. Cells treated with DDD00070762 did not grow after 24 or 48
h. (B) CAT reporter gene expression, under the control of the PAD1 3=UTR, increased after 24 and 48 h of treatment. GUS reporter gene expression, under
the control of a constitutive 3=UTR, showed variable expression levels between experiments after treatment (data not shown). (C) After 24 h of treatment,
80% of cells had an abnormal composition of DNA-containing organelles (nucleus [N] and kinetoplast [K]), from 250 cells per sample counted, in
contrast with cells treated with 100 M 8-pCPT-cAMP, where 
5% of cells had aberrant DNA content after 24 h. (D) Examples of cells treated with
DMSO, 8-pCPT-cAMP, or DDD00070762 for 24 h and 48 h are shown. Cells were stained with DAPI. Scale bar, 10 m. Error bars in all graphs represent
standard errors of the means (n 	 3).
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DDD00015314 treatment appears to cause a shift in the expres-
sion of several metabolic genes indicative of early steps in differ-
entiation in monomorphic cells.
DDD00015314 promotes the development to stumpy forms
in pleomorphic parasites. Given that DDD00015314 was able to
induce a partial differentiation phenotype in monomorphic try-
panosomes, we investigatedwhether this compoundwould have a
similar, or more pronounced, effect on pleomorphic cells natu-
rally competent for stumpy formation. Therefore, a pleomorphic
T. brucei bruceiAnTat 1.1 cell line was treated with 50, 10, or 5M
DDD00015314 for up to 48 h. At all concentrations tested,
DDD00015314 caused decreased population growth (Fig. 7A) and
accumulation inG1/G0 (Fig. 7B) equivalent to that induced by 100
M8-pCPT-cAMP. Since stumpy forms have an increased capac-
ity for differentiation to procyclic forms compared to slender
forms, cells that had been compound treated for 24 h were then
induced to differentiate to procyclic forms by the addition of 6
mM cis-aconitate and a temperature reduction to 27°C. Figure 7C
shows that DDD00015314-treated cells showed an increased level
of differentiation after 6 h, with a mean differentiation after
50 M, 10 M, and 5 M DDD00015314 treatment of 49.3%,
57.4%, and 59.7%, respectively, compared to 29.2% in cells
treated with DMSO alone (Fig. 7C). This was not, however, as
effective as 8-pCPT-cAMP exposure, nor did DDD00015314
treatment produce the levels of differentiation observed in in vivo-
derived stumpy forms, which had amean differentiation of 69.8%
and 88.2%, respectively. Moreover, by 24 h postinduction of dif-
ferentiation,DMSO-treated controls exhibited a higher level of EP
procyclin-positive parasites than DDD00015314-treated cells,
perhaps indicating that the treatment allows cells to embark on the
differentiation pathway but not sustain a proliferative procyclic
population.
As a final measure of the development to stumpy forms in-
duced by DDD00015314, we analyzed the expression of the
stumpy-specific marker protein, PAD1, by both flow cytometry
(Fig. 7D) and immunofluorescence microscopy (Fig. 7E). With
bothmethods, an increase in PAD1 protein expression in the pop-
ulation was observed after treatment with 8-pCPT-cAMP and at
all concentrations of DDD00015314 tested. Further, microscopy
revealed the presence of cells with intermediate and stumpy-like
morphology after 24 and 48 h of treatment with either 8-pCPT-
cAMP or DDD00015314 (Fig. 7E and Fig. 8). After 48 h of 50 M
DDD00015314 treatment, however, cells began to look mis-
shapen. Thus, although the effects ofDDD00015314 aremodest in
monomorphic cells, treatment of pleomorphic cells with this
compound has substantial effects, generating an accumulation in
G1/G0, expression of the PAD1 protein, increased capacity for the
initiation of differentiation to procyclic forms, andmorphological
changes associated with stumpy formation.
In conclusion, from a pilot screen of over 6,000 compounds
from a kinase-targeted library, a compound has been identified
that is able to specifically activate a reporter for stumpy-enriched
gene expression in monomorphic cell lines and induce a stumpy-
like phenotype in pleomorphic cell lines, as characterized by a
number of diagnostic assays. Moreover, an analysis of the tran-
scriptome of treated monomorphic cells revealed a modest but
consistent elevation of a number of transcripts known to be reg-
ulated during the development to stumpy forms in vivo. This
study, therefore, validates high-throughput screening as an ap-
proach to identify developmental regulators in trypanosome par-
asites. Moreover, a novel tool compound applicable for dissection
of components of this developmental pathway is identified.
DISCUSSION
Whole-cell-based high-throughput screening has been success-
fully utilized in Trypanosoma brucei research in the search for
compounds with trypanocidal or trypanostatic activity, with the
FIG 5 Compound DDD00015314 specifically causes a modest upregulation
of stumpy-specific reporter gene expression without causing upregulation of
constitutive reporter gene expression in monomorphic cells. 427 CAT-PAD1
3= UTR GUS-Const 3= UTR cells were treated with 50 M DDD00015314.
Negative-control cells were treated with 0.5% (vol/vol) DMSO; positive-con-
trol cells were treated with 100 M 8-pCPT-cAMP. (A) Population growth
was monitored at 24 and 48 h. Cells treated with DDD00015314 showed re-
duced growth compared to DMSO-treated controls. (B) CAT reporter gene
expression, under the control of the PAD1 3=UTR, increased after 24 and 48 h
of treatment. (C) GUS reporter gene expression, under the control of a con-
stitutive 3= UTR, was slightly reduced after 24 h of treatment with
DDD00015314; however, at 48 h GUS reporter gene expression was again
equivalent to that of DMSO-treated controls. Error bars in all graphs represent
standard errors of the means (n	 3).
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FIG 6 RNA-Seq on DDD00015314-treated cells reveals modest but specific changes in gene expression. (A) Scatter plot of log-normalized mean reads per
kilobase per million mapped reads (RPKM) for control and DDD00015314-treated cells based on two replicates, with values below the 20% quartile removed.
The PAD1 transcript is highlighted with a diamond. (B) Histogram showing absolute fold change of mRNA levels for selected genes that were up- and
downregulated after DDD00015314 treatment. PCF, procyclic form.
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TABLE 1 A truncated list of genes upregulated and downregulated in response to DDD00015314 treatmenta
Gene Descriptionb Groupc
Fold
change in
expression
Fold change in
slender vs stumpy
forms according
to:d
Capewell
et al.
Jensen
at al.
Upregulated genes
Tb927.11.6680 Amino acid permease/transporter, putative Amino acid metabolism transport 1.38 1.26 1.13
Tb927.7.4970 Glutamine synthetase, putative Amino acid metabolism transport 1.36 4.27 1.31
Tb927.10.3210 Delta-1-pyrroline-5-carboxylate dehydrogenase,
putative
Amino acid metabolism transport 1.31 1.25 1.54
Tb927.7.210 Proline dehydrogenase Amino acid metabolism transport 1.30 1.14 1.74
Tb927.9.5900 Glutamate dehydrogenase Amino acid metabolism transport 1.32 2.43 2.43
Tb927.7.170 ESAG9 protein, putative ESAG/GRESAG 1.75 1.75 2.58
Tb927.9.7340 ESAG9 protein, putative ESAG/GRESAG 1.50 NA 6.63
Tb927.8.7880 Receptor-type adenylate cyclase GRESAG 4
(pseudogene), putative
ESAG/GRESAG 1.38 1.53 NA
Tb927.3.540 ESAG1 (pseudogene), putative ESAG/GRESAG 1.27 2.75 NA
Tb927.9.16010 ESAG4 (pseudogene), putative ESAG/GRESAG 1.33 7.35 NA
Tb927.8.2540 3-Ketoacyl-CoA thiolase, putative Fatty acid metabolism 1.52 1.39 1.08
Tb927.11.16480 Enoyl-CoA hydratase/isomerase family protein,
putative
Fatty acid metabolism 1.30 1.56 1.55
Tb927.8.6110 Hydroxymethylglutaryl-CoA synthase Mitochondrial citrate cycle 1.30 1.88 1.09
Tb927.5.1710 Ribonucleoprotein p18, mitochondrial precursor,
putative
Mitochondrial citrate cycle 1.38 1.20 1.13
Tb927.9.3780 Putative mitochondrial pyruvate carrier 1 homolog Mitochondrial citrate cycle 1.26 2.51 1.15
Tb927.11.5280 ATPase subunit 9, putative Mitochondrial citrate cycle 1.30 1.70 1.20
Tb927.10.5050 Putative mitochondrial ATP synthase subunit Mitochondrial citrate cycle 1.27 3.63 1.22
Tb927.10.14000 Aconitase Mitochondrial citrate cycle 1.39 2.59 1.44
Tb927.5.3090 Putative mitochondrial ATP synthase subunit Mitochondrial citrate cycle 1.37 1.79 1.68
Tb927.10.7410 Succinyl-CoA ligase (GDP-forming) beta-chain,
putative
Mitochondrial citrate cycle 1.42 2.14 1.72
Tb927.5.3040 MIX protein Mitochondrial citrate cycle 1.37 1.04 1.75
Tb927.11.11680 2-Oxoglutarate dehydrogenase E2 component,
putative
Mitochondrial citrate cycle 1.28 1.06 2.28
Tb927.7.5930 PAD1 PAD family 1.44 1.17 1.23
Tb927.7.5940 PAD2 PAD family 1.37 1.70 1.84
Tb927.8.6170 Transketolase, putative Pentose phosphate pathway 1.32 3.15 2.16
Tb927.10.11220 PSSA-2 Procyclic form surface protein 1.31 5.78 1.55
Tb927.6.510 GPEET 2 procyclin precursor Procyclic form surface protein 1.71 3.88 8.51
Tb927.7.3320 ATG12/APG12, putative Protein/peptide degradation 1.25 1.06 1.36
Tb927.11.2500 Carboxypeptidase, putative Protein/peptide degradation 1.30 1.26 1.06
Tb927.10.12260 Cytosolic nonspecific dipeptidase, putative Protein/peptide degradation 1.45 2.99 1.59
Tb927.4.3940 Calpain-like cysteine peptidase, putative Protein/peptide degradation 1.33 1.87 1.71
Tb927.3.590 Adenosine transporter, putative Purine metabolism transport 1.44 2.21 1.59
Tb927.11.15530 C-14 sterol reductase, putative Steroid biosynthesis 1.28 2.56 1.56
Tb927.10.6910 Sterol methyltransferase, putative Steroid biosynthesis 1.28 3.08 NA
Tb927.10.6950 Sterol 24-c-methyltransferase, putative Steroid biosynthesis 1.25 4.07 NA
Tb927.10.12850 TTAGGG binding factor Other 1.36 1.18 1.07
Tb927.7.7110 LRRP, putative Other 1.36 1.34 1.01
Tb927.6.3130 Queuine tRNA-ribosyltransferase, putative Other 1.30 4.64 1.16
Tb927.7.7180 LRRP, putative Other 1.34 1.02 NA
Tb927.8.4100 FLA1-binding protein (FLA1BP) Other 1.26 1.47 NA
Downregulated genes
Tb927.10.9480 ESAG3 protein, putative ESAG/GRESAG 1.34 Inf Up 1.02
Tb927.7.3250 ESAG6 protein, putative ESAG/GRESAG 1.47 4.45 1.18
Tb927.7.3260 ESAG7 protein, putative ESAG/GRESAG 1.61 2.98 1.30
Tb927.9.16700 ESAG3 (pseudogene), putative ESAG/GRESAG 1.49 1.33 NA
Tb927.10.8440 Glucose transporter 1B Glucose transporter 1.85 2.39 1.28
Tb927.10.8450 Glucose transporter 1E Glucose transporter 1.96 3.01 1.17
Tb927.10.8530 Glucose transporter 2A Glucose transporter 1.26 1.27 1.08
(Continued on following page)
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aim of identifying new lead compounds for the development of
novel therapeutics against African trypanosomiasis (4–10). Here,
we explored the potential for using a similar screeningmethod for
the identification of compounds able to induce other trypano-
somephenotypes, namely, differentiation between life stages, pro-
viding possible tool compounds of value in research, as well as
therapeutics exploiting the irreversible proliferation arrest associ-
ated with the transition to stumpy forms. The fluorescence-based
approach developed was a rapid, inexpensive, and simple assay
able to be carried out in 96-well plate format, and autofluorescent
library compounds could be rapidly excluded in a cell-free assay
pre- or postscreening to identify cytologically relevant hits. As
such, over 6,000 compounds could be screened on fewer than 100
plates, requiring less than 1 liter of trypanosome culture. Smaller-
scale (and hence lower-cost) validation screening using a non-
fluorescence-based reporter that also allowed reporter-specific ef-
fects to be distinguished from general gene expression effects was
then exploited to unambiguously identify compounds able to
drive the developmental response under test.
From a starting point of 6,764 compounds, this screening
TABLE 1 (Continued)
Gene Descriptionb Groupc
Fold
change in
expression
Fold change in
slender vs stumpy
forms according
to:d
Capewell
et al.
Jensen
at al.
Tb927.10.8510 Glucose transporter, putative Glucose transporter 1.47 3.99 NA
Tb927.10.8500 Glucose transporter, putative Glucose transporter 1.36 1.79 NA
Tb927.10.8480 Glucose transporter, putative Glucose transporter 1.87 1.55 NA
Tb927.10.8460 Glucose transporter, putative Glucose transporter 1.83 1.46 NA
Tb927.10.8520 Glucose transporter, putative Glucose transporter 1.41 1.27 NA
Tb927.10.8470 Glucose transporter, putative Glucose transporter 1.74 1.18 NA
Tb927.10.8490 Glucose transporter, putative Glucose transporter 1.33 3.70 NA
Tb927.1.700 PGKC Glycosomal glycolysis/gluconeogenesis 1.30 5.38 2.19
Tb927.3.3270 ATP-dependent phosphofructokinase Glycosomal glycolysis/gluconeogenesis 1.34 6.47 1.80
Tb927.9.11600 Gim5B protein Glycosomal glycolysis/gluconeogenesis 1.65 2.96 1.75
Tb927.9.11580 Gim5A protein Glycosomal glycolysis/gluconeogenesis 1.37 1.03 1.61
Tb927.10.2010 Hexokinase (HK1) Glycosomal glycolysis/gluconeogenesis 1.51 1.84 1.51
Tb927.8.3530 Glycerol-3-phosphate dehydrogenase (NAD),
glycosomal
Glycosomal glycolysis/gluconeogenesis 1.29 2.31 1.38
Tb927.1.3830 Glucose-6-phosphate isomerase, glycosomal Glycosomal glycolysis/gluconeogenesis 1.28 4.85 1.37
Tb927.9.12590 Glycerol kinase, glycosomal (glk1) Glycosomal glycolysis/gluconeogenesis 1.36 3.06 1.25
Tb927.10.2020 Hexokinase (HK2) Glycosomal glycolysis/gluconeogenesis 1.42 1.36 1.36
Tb927.9.12550 Glycerol kinase, glycosomal (glk1) Glycosomal glycolysis/gluconeogenesis 1.34 3.38 NA
Tb927.9.12570 Glycerol kinase, glycosomal (glk1) Glycosomal Glycolysis/Gluconeogenesis 1.35 2.97 NA
Tb927.9.12610 Glycerol kinase, glycosomal (glk1) Glycosomal glycolysis/gluconeogenesis 1.29 2.96 NA
Tb927.9.12630 Glycerol kinase, glycosomal (glk1) Glycosomal glycolysis/gluconeogenesis 1.32 2.95 NA
Tb927.5.4200 Histone H4, putative Histone 1.35 14.81 NA
Tb927.5.4250 Histone H4, putative Histone 1.33 Inf
Down
NA
Tb927.11.900 Isocitrate dehydrogenase, putative Mitochondrial citrate cycle 1.34 1.10 1.06
Tb927.11.6330 6-Phosphogluconolactonase Pentose phosphate pathway 1.37 1.72 1.14
Tb927.3.2960 Inosine-adenosine-guanosine-nucleosidehydrolase Purine metabolism transport 1.81 6.55 2.06
Tb927.2.6240 Adenosine transporter 2 (TbNT5) Purine metabolism transport 1.34 2.75 1.12
Tb927.6.820 Pumilio RNA binding protein, putative (PUF4) RNA binding protein 1.30 1.32 1.21
Tb927.10.12760 Zinc finger protein family member, putative
(ZC3H36)
RNA binding protein 1.40 3.16 1.32
Tb927.9.11760 DNA repair protein RAD2, putative Other 1.30 1.38 1.07
Tb927.7.6220 Protein kinase, putative Other 1.38 2.29 1.11
Tb927.9.10170 Predicted zinc finger protein (homolog of Tbg
APC11)e
Other 1.33 1.08 1.12
a After 24 h of DDD00015314 treatment, 95 genes were upregulated, and 73 genes were downregulated greater than 1.2- fold. Further, the CAT reporter gene coupled to the PAD1
3= UTR showed a 1.47-fold increase in mRNA expression, similar to the 1.44-fold increase in PAD1 mRNA expression (highlighted in boldface). Here, hypothetical, VSG, and
retrotransposon hot spot protein genes have been removed for clarity. A full list of genes (with associated statistics) up- and downregulated after DDD00015314 treatment is
provided in Data Set S2 in the supplemental material. Product assignments were based on annotations and comments at TriTrypDB.org.
b ESAG, expression site-associated gene; PAD, protein associated with differentiation; CoA, coenzyme A; PSSA, procyclic form surface phosphoprotein; LRRP, leucine-rich repeat
protein; PGKC, phosphoglycerate kinase.
c, with or without.
d The absolute fold change in transcript abundance during complete differentiation from slender to stumpy forms as observed in two independent analyses (32, 33) is also shown
for each gene. In Capewell et al. (32) PAD1 was not distinguishable from other PAD family transcripts. NA, not available.
e Tbg, Trypanosoma brucei gambiense.
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FIG 7 Compound DDD00015314 causes a stumpy-like phenotype in pleomorphic bloodstream form cells. AnTat1.1 90:13 cells were treated with 50 M, 10
M, or 5 MDDD00015314. Negative-control cells were treated with 0.5% (vol/vol) DMSO; positive-control cells were treated with 100 M 8-pCPT-cAMP.
(A) Population growth was monitored at 24 and 48 h. Cells treated with DDD00015314 or 8-pCPT-cAMP showed reduced growth compared to DMSO-treated
controls. (B) Treatment with DDD00015314 or 8-pCPT-cAMP caused an accumulation of cells in G1/G0 after 24 and 48 h, as determined by flow cytometry of
DAPI-stained populations. (C) After 24 h of treatment, cells were induced to differentiate to procyclic forms by the addition of 6 mM cis-aconitate and a
temperature change from 37°C to 27°C. Cells treated with DDD00015314 or 8-pCPT-cAMP differentiated more efficiently than DMSO-treated cells by 6 h
postinduction, as determined by expression of EP procyclin. At 24 h however, cells treated with DDD00015314 had differentiated less well than DMSO-treated
cells. CCA, cis-aconitate. (D) Treated cells were fixed and stained for PAD1 protein expression and analyzed by flow cytometry. Cells treated withDDD00015314
or 8-pCPT-cAMP showed upregulation of PAD1 protein expression compared to negative controls after 24 and 48 h although to a lesser degree than that
observed from a stumpy form positive control. FITC, fluorescein isothiocyanate. (E) Immunofluorescence microscopy of cells after 24 h of treatment confirms
upregulation of PAD1 protein expression in DDD00015314- or 8-pCPT-cAMP-treated cells. Two examples are shown per treatment. In each pair, the left panel
shows a phase-contrast with DAPI image and the right panel shows the same cells stained for PAD1 protein. 1° Ab, primary antibody.
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method successfully identified three compounds able to induce
upregulation of PAD1 reporter gene expression as a proxy for
stumpy formation, and these were validated through follow-up
analysis. This confirmed the efficacy of the approach for detecting
specific cytological phenotypes distinct from generalized cyto-
static and cytotoxic effects likely to be elicited by a much broader
range of hit compounds. Two of the three hit compounds were
structurally very similar; the identification of both of these mole-
cules from a large compound set illustrates the consistency and
reproducibility of the method. Follow-up analysis confirmed that
the increase in PAD1 reporter gene expression induced by one of
these compounds (compound DDD00070762) was consistent
and reproducible. However, it did not represent a specific physi-
ological progression to a stumpy or stumpy-like form since the
constitutive reporter employed in the secondary screen exhibited
similar (though inconsistent) elevation and since the exposed cells
rapidly became multinucleated. Hence, these compounds may
target one or more processes in the cell that generate phenotypes
distinct from, or in addition to, a specific developmental response.
In contrast, the third compound identified, DDD00015314, did
cause specific upregulation of both PAD1 reporter gene activity
and endogenous PAD1 mRNA levels, without activation of the
constitutive reporter in monomorphic lines. Moreover, upon
treatment with DDD00015314, the cells underwent a change in
expression of a restricted set of genes, many of which are also
elevated upon stumpy formation in vivo. In particular, several
genes relating to energymetabolismwere elevated (mitochondrial
genes and enzymes involved in proline metabolism), whereas the
mRNA levels of a number of genes involved in glucose transport
and glycolysis were downregulated. These responses were limited
in extent (albeit similar in scale to those seen in the natural devel-
opmental process) but reproducible and indicative of a progres-
sion toward the stumpy phenotype in the monomorphic lines
used in the high-throughput screen. Treatment of pleomorphic
cells with the same compound had a more pronounced effect,
even at lower concentrations: cells displayed a stumpy-like phe-
notype with an accumulation of cells in G1/G0, expression of
PAD1 protein, and the presence of cells with an intermediate or
stumpy morphology within the population. Although the re-
sponse was not entirely physiological since the elevation of EP
procyclin expression at 6 h after exposure to cis-aconitate was
diminished after 24 h, the data indicate that compound
DDD00015314 is able to induce partial stumpy formation or ac-
tivate/inhibit some components of the stumpy formation path-
way.
Cell-permeable hydrolysable cAMP and AMP analogues have
been utilized for the induction of some, albeit not all, stumpy
characteristics in monomorphic cells, providing reagents to ana-
lyze some events of stumpy formation. Recently, a whole-genome
RNAi screen was designed to identify genes required for respon-
siveness to cAMP and AMP analogues in monomorphs, resulting
in the identification of multiple genes involved in physiological
stumpy formation in vivo. These represented the first known pos-
itive inducers of stumpy formation encompassingmolecules from
throughout the signaling cascade, including kinases, phosphata-
ses, and at least one predicted RNA binding protein (26). Clearly,
the outputs from high-throughput small-compound screens such
as the screen described here could provide reagents to further
dissect this pathway or other uncharacterized signaling pathways,
for example, by assisting in the ordering of components following
further genome-wide RNAi screens. Indeed, using multiple and
distinct chemical inducers of a full or partial stumpy-like pheno-
type would allow iterative RNAi screens, with resistance pheno-
types being observed only for molecules falling downstream of
where the compounds act on the signaling pathway. As com-
pound DDD00015314 appears to induce partial differentiation
toward stumpy formation, it could be targeting only some aspects
of the SIF signaling pathway, such that a whole-genome RNAi
screen with this compound could identify genes involved in a
specific branch of a stumpy formation cascade as well as those
shared with the response to cell-permeable cAMP/AMP. Cur-
rently, the limited availability of compound DDD00015314 and
its expense preclude such analysis with a monomorphic RNAi
library (44); however, the enhanced sensitivity of pleomorphic
cells could permit this analysis if RNAi libraries could be gen-
erated at sufficient coverage in these cell lines. Alternatively,
DDD00015314 could be chemically refined to increase its potency
and specificity in order to potentially achieve activity at lower
concentrations. This provides a starting point, and proof of prin-
ciple, for the development of further tools for the study of try-
panosome differentiation and developmental gene regulation.
Compounds driving complete or incomplete stumpy forma-
tion also offer potential as a complementary or adjunctive ap-
proach to trypanocidal therapeutics, generating a reduction of
parasite virulence or transmission between hosts. Hence, acceler-
ated differentiation of slender forms to stumpy forms within the
FIG 8 Compound DDD00015314 causes a stumpy-like morphology in pleo-
morphic bloodstream form cells.Microscope images of treated cells reveal that
DDD00015314 or 8-pCPT-cAMP treatment induces a stumpy-like phenotype
after 24 h. This morphology remains apparent in cells treated with 5 or 10M
DDD00015314 or with 8-pCPT-cAMP after 48 h, but many cells treated with
50 M DDD00015314 have an aberrant morphology after 48 h.
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bloodstream could reduce transmission in epidemic situations by
reducing the density of stumpy forms below that needed for effec-
tive tsetse passage. Perhaps more importantly, where a complete
differentiation of parasites into stumpy forms could be achieved
in the bloodstream, a trypanostatic response (stumpy formation)
would inevitably lead to a trypanocidal outcome through the ac-
tion of the immune response (45), clearing the infection. Unlike
conventional therapies, this approach could also be evolution re-
sistant since emergent resistant parasites, while more virulent in
the originating host, would have reduced transmissibility through
their reduced rate of stumpy formation, preventing the propaga-
tion of resistance in a population.
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